In a nutshell This study evaluated the efficacy of a program for home-based, sustainable, lifestyle changes in older sedentary prostate cancer (PCa) survivors. Main findings: participants demonstrated and maintained healthy dietary behaviors, physical activity and functional ability. Some background Older PCa survivors are at risk of developing...
Read More
In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...
Read More
Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...
Read More
The aim of this article was to describe some of the most interesting developments concerning new therapies for advanced prostate cancer. During the last years new experimental therapeutic agents for the treatment of advanced prostate cancer have been developed. These are based on the recent discoveries on prostate cell function, resistance to...
Read MoreIn a nutshell The present study compared the survival benefits of two drug combinations used for adjuvant chemotherapy: Capecitabine/Oxaliplatin (Xelox) versus Fluorouracil/Folinic Acid (FU/FA). The study found Xelox to be a superior therapy for stage III colon cancer. Some background Stage III colon cancer is cancer...
Read More
Colorectal cancer (CRC) is one of the main causes of cancer related deaths. Patients diagnosed with CRC are treated with surgery to remove the tumor and affected tissue. If the tumor affects the entire thickness of the colon or rectal wall it is referred to as being stage II; if the local lymph nodes are also affected the cancer is referred to as being a...
Read More
In a nutshell This clinical trial evaluated the survival benefits of a drug named Enzalutamide (Xtandi) for patients with non-responsive (refractory) advanced prostate cancer previously treated with chemotherapy. Main findings: Enzalutamide prolonged survival by approximately 5 months and reduced the risk of death by 37%. Some background The...
Read More
In a nutshell This study evaluated whether focal Ultrasound-based therapy of individual cancer lesions can minimize the side effects associated with radical therapy that involves the whole prostate gland. Main findings: Focused therapy directed into cancer tissues significantly reduces genitourinary side effects like urine-leakage and impotence. Some...
Read More
In a nutshell This study aimed to identify health-related decline in quality of life 4 to 8 years after prostate cancer (PC) treatment. Main finding: measures of quality of life vary based on therapy choice. Some background Treatments for localized PC (confined to the prostate gland) include radical prostatectomy (RP), brachytherapy (BT) and...
Read More
In a nutshell This study compared intermittent versus continuous androgen deprivation therapy (ADT) for localized (confined) prostate cancer due to prostate-specific antigen (PSA) elevation after radiotherapy. Main findings: Intermittent ADT was not inferior compared to continuous therapy with respect to survival. However, some quality of life...
Read More
This review article describes clinical evidence of the benefits and risks of a treatment combined of a short course of hormonal therapy (termed ‘androgen deprivation therapy’, ADT) and radiation given in escalated doses. Patients involved were those with localized prostate cancer but higher Gleason score or prostate-specific antigen (PSA)...
Read MoreIn a nutshell This article reviewed the possible complications that can occur after radiation therapy for prostate cancer. Some background Radiation therapy (RT) is usually given as part of prostate cancer management. RT improves the prognosis of prostate cancer by limiting the rate of recurrence (return of cancer). In early stages, RT can even...
Read More
